THE EFFECT OF EXEMESTANE ON MENOPAUSE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND A COMPARISON WITH CLINICIAN-REPORTED TOXICITIES: AN ANALYSIS OF THE NCIC CTG MAP.2 CHEMOPREVENTION TRIAL
Background: Exemestane is a drug of great interest for breast cancer prevention, because it inhibits estrogen production. Estrogen may operate by increasing breast density, a well-established biomarker for increased breast cancer risk. The NCIC CTG MAP.2 trial examined the efficacy of exemestane in...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en en |
| Published: |
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1974/7271 |